Is Tempest Therapeutics, Inc. (TPST) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 49.3% / 30% | 97.2% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 49.3% / 33% | 97.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 37.0% / 33% | 73.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 49.3% / 33% | 97.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 37.0% / 33% | 73.0% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -405.0% | |
| Return on Assets (ROA) | -89.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$33M |
| Free Cash Flow | -$33M |
| Total Debt | $15M |
| Debt-to-Equity | 132.4 |
| Current Ratio | 2.3 |
| Total Assets | $41M |
Price & Trading
| Last Close | $1.66 |
| 50-Day MA | $2.37 |
| 200-Day MA | $6.21 |
| Avg Volume | 105K |
| Beta | -2.2 |
|
52-Week Range
$1.56
| |
About Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Tempest Therapeutics, Inc. (TPST) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Tempest Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Tempest Therapeutics, Inc.'s debt ratio?
Tempest Therapeutics, Inc.'s debt ratio is 49.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 37.0%.
What are Tempest Therapeutics, Inc.'s key financial metrics?
Tempest Therapeutics, Inc. has a market capitalization of $23M. Return on equity stands at -405.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.